Brief: Valbiotis Succeeds In Industrial Production Of Valedia

Valbiotis SA

28/05/2019 16:44

May 28 (Reuters) - VALBIOTIS SAS  ALVAL.PA :
    * VALBIOTIS SUCCEEDS IN THE INDUSTRIAL PRODUCTION OF
VALEDIA®, A
MAJOR SCIENTIFIC INNOVATION FOR PREDIABETIC PEOPLE, IN
COLLABORATION WITH THE PIERRE FABRE GROUP
    * CONFIRMATION OF VALBIOTIS'S CAPACITY TO PRODUCE VALEDIA®
IN
COMPLIANCE WITH NORTH AMERICAN AND EUROPEAN INDUSTRIAL STANDARDS
    * A KEY STAGE IN HEALTH CLAIM APPLICATION FOR TWO LEADING
MARKETS
WORLDWIDE, NORTH AMERICA AND EUROPE
    * ACCOMPLISHMENT DUE TO COMBINED EXPERTISE OF VALBIOTIS AND
PIERRE
FABRE GROUP, WHICH SPECIALIZES IN INDUSTRIAL MANUFACTURE OF
PLANT-BASED PRODUCTS
    * RESULTS OF FIRST INTERNATIONAL PHASE IIA STUDY ARE
EXPECTED
BEFORE 31 JULY 2019
    * LAUNCH OF VALEDIA(®) IS PLANNED FOR 2021, WITH A HEALTH
CLAIM
FOR REDUCING RISK OF TYPE 2 DIABETES
    * TOTUM-63 HAS ALREADY BEEN PROVEN SAFE AND EFFECTIVE IN
HEALTHY
HUMAN VOLUNTEERS DURING A PHASE I/II CLINICAL STUDY
    * THIS STEP COMPLETES OUR HEALTH CLAIM APPLICATION AND
SUPPORTS
OUR NEGOTIATIONS WITH A PARTNER COMPANY TO MARKET PRODUCT IN
2021 - CEO

Source text for Eikon:  ID:nBw3FhbJha 
Further company coverage:  ALVAL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))